Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Atrial fibrillation AF is a major cause of heart-related illness and death, especially among Asian patients who face higher risks of serious bleeding such as brain hemorrhage compared to non-Asians. This research, called the COhort of antithrOmbotic use and cLinical outcomes in patients with Atrial Fibrillation COOL-AF Phase 2, aims to study how antithrombotic medication use changes over time and how these changes affect health outcomes in people with AF. The study is observational and conducted across multiple centers in Thailand. Participants in this study have known or newly diagnosed non-valvular AF and are followed without any intervention or treatment assigned by the study. The study plans to enroll about 3680 patients over two years from 33 centers. Participants will be monitored every 6 months for up to 3 years to observe patterns of medication use, particularly warfarin and non-vitamin K antagonist oral anticoagulants NOACs, and clinical events including stroke, systemic embolism, bleeding, heart attacks, and heart failure. Throughout the study, patients will have regular check-ins every six months to track their medication usage and health status. Researchers will collect data on important outcomes such as rates of stroke, bleeding events, and quality of life. The studys primary focus is on long-term safety and effectiveness of antithrombotic treatments in this population. The total participation duration can be up to 3 years, ensuring thorough observation of clinical outcomes and treatment patterns.
Actively Recruiting
The RAPID trial is a Phase 4, multinational, multicenter study assessing the clinical impact of rapid microbiological diagnostics combined with antimicrobial stewardship and early targeted antibiotic therapy compared to standard diagnostics and antibiotics. It focuses on hospitalized adults with bloodstream infections, hospital-acquired pneumonia, or ventilator-associated pneumonia, particularly infections caused by Pseudomonas aeruginosa or carbapenem-resistant Enterobacterales. The trial aims to determine if this approach improves outcomes such as mortality and organ failure scores. Participants are randomly assigned to either an intervention group receiving rapid diagnostic testing using the BioFire BCID2 Panel for blood cultures or the BioFire FilmArray Pneumonia Panels for respiratory samples, alongside early availability of ceftazidime-avibactam if appropriate, or to a control group receiving standard diagnostic and antibiotic care according to local practice. Rapid testing occurs within four hours of Gram-negative bacilli detection, and antibiotic therapy is guided by stewardship protocols and conventional susceptibility results. During the 60-day follow-up, participants undergo clinical assessments, mortality tracking, and evaluations of antibiotic use, microbiological outcomes, resistance development, and functional status. Repeat cultures and whole-genome sequencing of bacterial isolates are performed to monitor bacterial persistence and resistance. The primary outcome measures a composite of all-cause mortality or lack of improvement in organ failure SOFA score at Day 14 after the initial culture.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a long-term observational study across three microbiology units in hospitals and community health systems in Thailand, Lao PDR, and Cambodia. The study focuses on melioidosis, aiming to understand how the environment, pathogen, and host interact to influence disease development and outcomes. It includes patients diagnosed with melioidosis, matched healthy controls, and residents of a high-risk community known as the Sandbox Village. Patients with melioidosis will be followed at six time points from hospital admission through one year post-discharge to collect clinical data on demographics, medical history, environmental exposures, treatment, adherence, and outcomes. Healthy controls matched by age, sex, and village will provide blood samples at enrollment and receive follow-up calls at 6 and 12 months. The Sandbox Village cohort will involve approximately 400 residents monitored intensively over 42 months, with periodic blood samples collected every two months to assess antibody responses. Participants will undergo various assessments including blood sampling, telephone follow-ups, and clinical data collection. Researchers will measure outcomes such as melioidosis development after exposure, mortality during the acute phase, and hospital readmissions for patients, while controls and community residents will be monitored for subclinical infections and environmental influences. The study spans up to 3.5 years for community participants and one year for patients and controls, with ongoing observation and data collection to better understand melioidosis risks and recovery.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the epidemiological impact and cost-effectiveness of long-acting antiretrovirals for HIV prevention among Thai men who have sex with men MSM and transgender women TGW. The study includes discrete choice experiments DCEs to understand preferences for different pre-exposure prophylaxis PrEP options, as well as analysis of routine service data. The findings will guide mathematical modeling of long-acting PrEP uptake and its impact on HIV prevention. The study has three phases. Phase I involves in-depth interviews IDIs and focus group discussions FGDs with current, previous, or interested PrEP users to identify important attributes for PrEP choices. Phase II pilots the DCEs with convenience samples to refine the survey. Phase III launches two final surveys for MSM and TGW, collecting data on demographics, risk behavior, HIV and STI testing, PrEP knowledge, use, and preferences across attributes like product form, dosing frequency, provider type, and cost. Participants will take part in interviews, group discussions, and surveys conducted either in person or online. Data collected includes sociodemographic information, risk behaviors, PrEP attitudes, and preferences. Researchers will measure the projected uptake of long-acting PrEP, epidemiological impact, and cost-effectiveness over 12 to 18 months. The study includes ongoing monitoring of participant responses to optimize understanding of factors influencing PrEP use.